tbuckley/cabot-search huggingface dataset:
Justice, Vulnerable Populations, and the Use of Conversational AI in Psychotherapy
Authors: Bennett Knox, Pierce Christoffersen, Kalista Leggitt, Zeia Woodruff, Matthew H. Haber
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Conversational Artificial Intelligence in Psychotherapy: A New Therapeutic Tool or Agent? Additional informationFundingChristoffersen, Leggitt, and Woodruff received funding for this project from the University of Utah Office of Undergraduate Research.
Deception Mode: How Conversational AI Can Respect Patient Autonomy
Authors: Jesse Gray
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Conversational Artificial Intelligence in Psychotherapy: A New Therapeutic Tool or Agent? Additional informationFundingThis work was supported by the European Research Council (ERC) under the European Union's Horizon 2020 research and innovation program (grant agreement no. 949841).
Relational Reciprocity from Conversational Artificial Intelligence in Psychotherapy
Authors: Lillian Carol Wieland
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Conversational Artificial Intelligence in Psychotherapy: A New Therapeutic Tool or Agent? Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Artificial Womb on Maternal Request and Without the Father’s Consent: Ethical Perspectives Through a Principlist Approach
Authors: Matteo Gulino, Pasquale Ricci, Gianluca Montanari Vergallo
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Ethics Considerations Regarding Artificial Womb Technology for the Fetonate DISCLOSURE STATEMENTNo potential conflict of interest was reported by the author(s).Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Lost in Gestation: On Fetonates, Perinates, and Gestatelings
Authors: Lien De Proost, Geertjan Zuijdwegt
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Ethics Considerations Regarding Artificial Womb Technology for the Fetonate Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Presidential Symposium and Presentation of Top Abstracts
Journal: Molecular Therapy (2023)

collection rate and time from Mozobil administration.Following the completion of the apheresis procedure, the apheresis product was subjected to a coll density gradient separation to isolate mononuclear cells.e mononuclear cell fraction was then immunomagnetically depleted of CD11b+ cells and the CD11b-fraction was once more stained, this time with anti-CD34 immunomagnetic beads to allow positive selection of CD34+ cells.Our methods have produced 73 to 95% purity of CD34+ cells across our studies, with a cell yield between 1.34 to 53.4 x 10 6 CD34+ cells across studies.Preliminary analysis of samples collected during the apheresis procedures suggested that while total cell counts were comparable across collection conditions, there were higher concentrations of CD45+CD34+ cells in samples collected within 5-6.20hrs post-mozobil administration, than later collections (up to 7.30hrs post-mozobil administration).In addition, when collected during the earlier timeframe, a higher concentration of CD45+CD34+ cells was obtained in a sample with a collection rate of 0.5mL/min, as compared to 1mL/min.Finally, the collection color (used as an index of cells density during collection), howed a trend to greater CD45+CD34+ concentration in samples collected in the following order: dark and middle then pale red patterns.We demonstrate high degrees of purity (>70%) in isolating CD34+ cells from apheresis product of non-human primates by immunomagnetic bead separation. is method can be harnessed to produce a large variety of cells for immunotherapies, as well as to develop, test, and bring to market CAR T cells produced though allogenic methods.
Tools, Agents or Something Different? – The Importance of Techno-Philosophical Premises in Analyzing Health Technology
Authors: Joschka Haltaufderheide, Robert Ranisch
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Conversational Artificial Intelligence in Psychotherapy: A New Therapeutic Tool or Agent? Additional informationFundingThis work was supported by the VolkswagenStiftung under Grant 9B 233 (Digital Medical Ethics Network).
Artificial Placenta – Imminent Ethical Considerations for Research Trials and Clinical Translation
Authors: E. J. (Joanne) Verweij, Elselijn Kingma
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Ethics Considerations Regarding Artificial Womb Technology for the Fetonate Additional informationFundingThis work was supported by H2020 European Research Council. Grant Number: 679586 Framework Programme; ZonMW Klinisch Fellowship 90719039.
Artificial Wombs or Artificial Feminism: What Is Wrong With Being Pregnant?
Authors: Tessa Gavina, Chris Gastmans, Alice Cavolo
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Ethics Considerations Regarding Artificial Womb Technology for the Fetonate Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Tools and/or Agents? Reflections on Sedlakova and Trachsel’s Discussion of Conversational Artificial Intelligence
Authors: Sven Nyholm
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Conversational Artificial Intelligence in Psychotherapy: A New Therapeutic Tool or Agent? Additional informationFundingThe author(s) reported there is no funding associated with the work featured in this article.
Is the Mother’s Decision to Opt for Artificial Womb Technology Always “Supererogatory”?
Authors: Kyoko Takashima, Tomohide Ibuki, Keiichiro Yamamoto
Journal: The American Journal of Bioethics (2023)

Click to increase image sizeClick to decrease image sizeThis article refers to:Ethics Considerations Regarding Artificial Womb Technology for the Fetonate Additional informationFundingThis research was supported by JST-RISTEX under Grant Number 22-221037880
Severe Mental Illness and Type 2 Diabetes Outcomes and Complications: A Nationwide Cohort Study
Authors: Kelly J. Fleetwood, Sarah H. Wild, Kirsty A.M. Licence, Stewart W. Mercer, Daniel J. Smith, Caroline A. Jackson
Journal: Diabetes Care (2023)

OBJECTIVE To compare cardiovascular and mortality outcomes in people with severe mental illness (SMI) versus no mental illness in a national cohort study of people with type 2 diabetes. RESEARCH DESIGN AND METHODS We included adults diagnosed with type 2 diabetes between 2004 and 2018 from the national Scottish diabetes register, ascertaining history of mental illness from linked psychiatric and general hospital admission records. We identified major cardiovascular disease (CVD) events, all-cause mortality, and CVD-specific mortality through record linkage. Using Cox regression, we estimated hazard ratios (HRs) for associations between SMI and outcomes, adjusting for baseline sociodemographic and clinical characteristics, including history of CVD, comorbidity, hypertension, high cholesterol, HbA1c, BMI, alcohol use disorder, and smoking. RESULTS Among 259,875 people with type 2 diabetes, 1.0%, 0.5%, and 3.0% had schizophrenia, bipolar disorder, and major depression, respectively. After adjusting for sociodemographic characteristics, the risk of major CVD events was higher in people with schizophrenia (HR 1.22, 95% CI 1.06–1.41), bipolar disorder (HR 1.58, 95% CI 1.33–1.87), and major depression (HR 1.59, 95% CI 1.49–1.70) compared with people without a history of mental illness. SMI was also associated with an approximately twofold increased risk of CVD-specific and all-cause mortality. All associations attenuated following further adjustment for clinical characteristics. CONCLUSIONS Among people with diabetes, people with a history of SMI have poorer cardiovascular and mortality outcomes compared with those without mental illness. While the underlying mechanisms are further investigated, effective prevention and management of cardiovascular risk factors is needed in this high-risk group.
Matt Morgan: Is medicine no longer a vocation?
Authors: Matt Morgan
Journal: BMJ (2023)

Is medicine no longer a vocation?Matt Morgan consultant in intensive care medicine Junior doctors in the UK have recently gone on strike simply in a bid to be paid the same as sandwich shop workers, and the naysayers have been dusting off familiar playbooks used by governments in years past.For those with a genuine interest in truth and in resolving the dispute, any arguments around doctors' relative pay, inflation, lifetime earnings, pensions, and international comparisons should quickly turn to ash.That leaves only the political choice of where finite resources should be directed.And this is where the actual debate, difficult decisions, discussion-and, hopefully, resolution-should lie.But one claim often waged against doctors can feel like an uncomfortable truth.It is one that needs to be extinguished rather than left to smoulder.When other arguments have been exhausted, cynics retort that "being a doctor is a calling, a vocation, a privilege" and that "vocation has nothing to do with pay."Are they right?Or is vocation dead?Some say good riddance to vocation.Why should a health system be powered by guilt, endless duty, and sacrifice rather than by safe working conditions, fair pay, and patient centred reorganisation?Some say that they do come to work mainly to be paid.That it is in fact just a job.And for those people, perhaps this view is an antidote to burnout-you can't burn out if there's no fuel in your fire.But I take a different view.For me, pay is a requirement but in no way sufficient.I would rather "burn in" through believing that I've made a difference, gone that extra mile, and worked at something that's more than just a job.I do have a vocation and not just a function.But that can't shackle me from shouting "No!" on occasion.I can still say that enough is enough.I can still put my worth, and that of my colleagues, at the front when needed.In fact, I, and all of us, must.For having a vocation is not just about now.It's about the future, about ensuring that there'll be something for others to be called towards.A profession that can continue to care for patients and their families.Not a just functional job that was kept limping along, fuelled by guilt, duty, and sacrifice, until it fell face first into the fire.Vocation is not dead.But it is being strangled.You can be called to something only if those already there have enough breath to beckon you to join them.Asking for fairness, pay restoration, better conditions, or negotiations at the very least, but still being left with industrial action as your only option, is not evidence that vocation is dead.This is evidence that it's still alive.
Large pedunculated colorectal polyps: more than meets the eye
Authors: Steven J. Heitman
Journal: Endoscopy (2023)

The effectiveness of screening-related colonoscopy in the prevention of colorectal cancer (CRC) hinges on the identification and removal of precancerous polyps [1]. It is now firmly established that the overwhelming majority of all colorectal polyps can be resected endoscopically, thereby avoiding surgery, which is associated with greater risks and is more costly [2]. Nevertheless, post-colonoscopy colorectal cancers occur among patients who have undergone one or more colonoscopies, where both missed and incompletely resected polyps are recognized risk factors for this undesirable outcome [3].
European Association of Nuclear Medicine (EANM) Focus 4 consensus recommendations: molecular imaging and therapy in haematological tumours
Authors: Cristina Nanni, Carsten Kobe, Bettina Baeßler, Christian Baues, Ronald Boellaard, Peter Borchmann, Andreas Buck, Irène Buvat, Björn Chapuy, Bruce D Cheson, Robert Chrzan, Ann-Segolene Cottereau, Ulrich Dührsen, Live Eikenes, Martin Hutchings, Wojciech Jurczak, Françoise Kraeber-Bodéré, Egesta Lopci, Stefano Luminari, Steven MacLennan, N George Mikhaeel, Marcel Nijland, Paula Rodríguez-Otero, Giorgio Treglia, Nadia Withofs, Elena Zamagni, Pier Luigi Zinzani, Josée M Zijlstra, Ken Herrmann, Jolanta Kunikowska
Journal: The Lancet Haematology (2023)
Cognitive functional therapy with or without movement sensor biofeedback versus usual care for chronic, disabling low back pain (RESTORE): a randomised, controlled, three-arm, parallel group, phase 3, clinical trial
Authors: Peter Kent, Terry Haines, Peter O'Sullivan, Anne Smith, Amity Campbell, Robert Schutze, Stephanie Attwell, J P Caneiro, Robert Laird, Kieran O'Sullivan, Alison McGregor, Jan Hartvigsen, Den-Ching A Lee, Alistair Vickery, Mark Hancock
Journal: The Lancet (2023)
Single-arm studies involving patient-reported outcome data in oncology: a literature review on current practice
Authors: Limin Liu, Jungyeon Choi, Jammbe Z Musoro, Willi Sauerbrei, Cecilie Delphin Amdal, Ahu Alanya, Yolanda Barbachano, Joseph C Cappelleri, Ragnhild Sørum Falk, Mallorie H Fiero, Antoine Regnault, Jaap C Reijneveld, Rickard Sandin, Doranne Thomassen, Satrajit Roychoudhury, Els Goetghebeur, Saskia le Cessie, Olalekan Lee Aiyegbusi, Ahu Alanya, Yolanda Barbachano, Ethan Basch, Melanie Calvert, Alicyn Campbell, Joseph Cappelleri, Jungyeon Choi, Samantha Cruz Rivera, Cecilie Delphin Amdal, Mallorie Fiero, Els Goetghebeur, Rajesh Kamalakar, Karen Keating, Paul Kluetz, Saskia le Cessie, Limin Liu, Geert Molenberghs, Jammbe Musoro, David Ness, Khadija Rantell, Antoine Regnault, Jaap Reijneveld, Satrajit Roychoudhury, Gerhard Rumpold, Alexander Russell-Smith, Claudia Rutherford, Kavita Sail, Rickard Sandin, Maxime Sasseville, Willi Sauerbrei, Anja Schiel, Michael Schlichting, Kathy Soltys, Ragnhild Sorum Falk, Yun Su, Silene ten Seldam, Doranne Thomassen, Kelly Van Lancker
Journal: The Lancet Oncology (2023)
Repeated blood–brain barrier opening with an implantable ultrasound device for delivery of albumin-bound paclitaxel in patients with recurrent glioblastoma: a phase 1 trial
Authors: Adam M Sonabend, Andrew Gould, Christina Amidei, Rachel Ward, Karyn A Schmidt, Daniel Y Zhang, Cristal Gomez, John F Bebawy, Benjamin P Liu, Guillaume Bouchoux, Carole Desseaux, Irene B Helenowski, Rimas V Lukas, Karan Dixit, Priya Kumthekar, Víctor A Arrieta, Maciej S Lesniak, Alexandre Carpentier, Hui Zhang, Miguel Muzzio, Michael Canney, Roger Stupp
Journal: The Lancet Oncology (2023)
Defining the road map to a UK national lung cancer screening programme
Authors: Emma L O'Dowd, Richard W Lee, Ahsan R Akram, Emily C Bartlett, Stephen H Bradley, Kate Brain, Matthew E J Callister, Yan Chen, Anand Devaraj, Sinan R Eccles, John K Field, Jesme Fox, Seamus Grundy, Sam M Janes, Martin Ledson, Melanie MacKean, Anne Mackie, Kieran G McManus, Rachael L Murray, Arjun Nair, Samantha L Quaife, Robert Rintoul, Anne Stevenson, Yvonne Summers, Louise S Wilkinson, Richard Booton, David R Baldwin, Philip Crosbie
Journal: The Lancet Oncology (2023)
Exploring cellular senescence in the musculoskeletal system: Any insights for biomarkers discovery?
Authors: Laura Gerosa, Amir Mohammad Malvandi, Marco Malavolta, Mauro Provinciali, Giovanni Lombardi
Journal: Ageing Research Reviews (2023)

The locomotor system comprises skeletal muscles and bones with active metabolism and cellular turnover. Chronic locomotor system disorders gradually arising with aging are inversely associated with the correct function of bone and muscles. Senescent cells appear more frequently in advanced ages or pathological conditions, and the accumulation of senescent cells in muscle tissue negatively correlates with muscle regeneration, which is crucial for maintaining strength and preventing frailty. Senescence in the bone microenvironment, osteoblasts, and osteocytes affects bone turnover favoring osteoporosis. It is likely that in response to injury and age-related damage over the lifetime, a subset of niche cells accumulates oxidative stress and DNA damage beyond the threshold that primes the onset of cellular senescence. These senescent cells may acquire resistance to apoptosis that, combined with the weakened immune system, results in impaired clearance of senescent cells and their accumulation. The secretory profile of senescent cells causes local inflammation, further spreading senescence in neighboring niche cells and impairing tissue homeostasis. The resulting impairment of turnover/tissue repair in the musculoskeletal system reduces the efficiency of the organ in response to environmental needs that finally lead to functional decline. Management of the musculoskeletal system at the cellular level can benefit the quality of life and reduce early aging. This work discusses current knowledge of cellular senescence of musculoskeletal tissues to conclude with biologically active biomarkers effective enough to reveal the underlying mechanisms of tissue flaws at the earliest possible.
Overexpression of blaGES-1 due to a strong promoter in the class 1 integron contributes to decreased ceftazidime-avibactam susceptibility in carbapenem-resistant Pseudomonas aeruginosa ST235
Authors: Xi Li, Xiaofan Zhang, Heng Cai, Yiwei Zhu, Jingshu Ji, Tingting Qu, Yuexing Tu, Hua Zhou, Yunsong Yu
Journal: Drug Resistance Updates (2023)
Engineered biochemical cues of regenerative biomaterials to enhance endogenous stem/progenitor cells (ESPCs)-mediated articular cartilage repair
Authors: Liangbin Zhou, Jietao Xu, Andrea Schwab, Wenxue Tong, Jiankun Xu, Lizhen Zheng, Ye Li, Zhuo Li, Shunxiang Xu, Ziyi Chen, Li Zou, Xin Zhao, Gerjo J.V.M. van Osch, Chunyi Wen, Ling Qin
Journal: Bioactive Materials (2023)

As a highly specialized shock-absorbing connective tissue, articular cartilage (AC) has very limited self-repair capacity after traumatic injuries, posing a heavy socioeconomic burden. Common clinical therapies for small- to medium-size focal AC defects are well-developed endogenous repair and cell-based strategies, including microfracture, mosaicplasty, autologous chondrocyte implantation (ACI), and matrix-induced ACI (MACI). However, these treatments frequently result in mechanically inferior fibrocartilage, low cost-effectiveness, donor site morbidity, and short-term durability. It prompts an urgent need for innovative approaches to pattern a pro-regenerative microenvironment and yield hyaline-like cartilage with similar biomechanical and biochemical properties as healthy native AC. Acellular regenerative biomaterials can create a favorable local environment for AC repair without causing relevant regulatory and scientific concerns from cell-based treatments. A deeper understanding of the mechanism of endogenous cartilage healing is furthering the (bio)design and application of these scaffolds. Currently, the utilization of regenerative biomaterials to magnify the repairing effect of joint-resident endogenous stem/progenitor cells (ESPCs) presents an evolving improvement for cartilage repair. This review starts by briefly summarizing the current understanding of endogenous AC repair and the vital roles of ESPCs and chemoattractants for cartilage regeneration. Then several intrinsic hurdles for regenerative biomaterials-based AC repair are discussed. The recent advances in novel (bio)design and application regarding regenerative biomaterials with favorable biochemical cues to provide an instructive extracellular microenvironment and to guide the ESPCs (e.g. adhesion, migration, proliferation, differentiation, matrix production, and remodeling) for cartilage repair are summarized. Finally, this review outlines the future directions of engineering the next-generation regenerative biomaterials toward ultimate clinical translation.
Transcriptional derepression of CHD4/NuRD-regulated genes in the muscle of patients with dermatomyositis and anti-Mi2 autoantibodies
Authors: Iago Pinal-Fernandez, Jose Cesar Milisenda, Katherine Pak, Sandra Muñoz-Braceras, Maria Casal-Dominguez, Jiram Torres-Ruiz, Stefania Dell'Orso, Faiza Naz, Gustavo Gutierrez-Cruz, Yaiza Duque-Jaimez, Ana Matas-Garcia, Joan Padrosa, Francesc J Garcia-Garcia, Mariona Guitart-Mampel, Gloria Garrabou, Ernesto Trallero-Araguás, Brian Walitt, Julie J Paik, Jemima Albayda, Lisa Christopher-Stine, Thomas E Lloyd, Josep Maria Grau-Junyent, Albert Selva-O'Callaghan, Andrew Lee Mammen
Journal: Annals of the Rheumatic Diseases (2023)

Myositis is a heterogeneous family of diseases including dermatomyositis (DM), immune-mediated necrotising myopathy (IMNM), antisynthetase syndrome (AS) and inclusion body myositis (IBM). Myositis-specific autoantibodies define different subtypes of myositis. For example, patients with anti-Mi2 autoantibodies targeting the chromodomain helicase DNA-binding protein 4 (CHD4)/NuRD complex (a transcriptional repressor) have more severe muscle disease than other DM patients. This study aimed to define the transcriptional profile of muscle biopsies from anti-Mi2-positive DM patients.RNA sequencing was performed on muscle biopsies (n=171) from patients with anti-Mi2-positive DM (n=18), DM without anti-Mi2 autoantibodies (n=32), AS (n=18), IMNM (n=54) and IBM (n=16) as well as 33 normal muscle biopsies. Genes specifically upregulated in anti-Mi2-positive DM were identified. Muscle biopsies were stained for human immunoglobulin and protein products corresponding to genes specifically upregulated in anti-Mi2-positive muscle biopsies.A set of 135 genes, including SCRT1 and MADCAM1, was specifically overexpressed in anti-Mi2-positive DM muscle. This set was enriched for CHD4/NuRD-regulated genes and included genes that are not otherwise expressed in skeletal muscle. The expression levels of these genes correlated with anti-Mi2 autoantibody titres, markers of disease activity and with the other members of the gene set. In anti-Mi2-positive muscle biopsies, immunoglobulin was localised to the myonuclei, MAdCAM-1 protein was present in the cytoplasm of perifascicular fibres, and SCRT1 protein was localised to myofibre nuclei.Based on these findings, we hypothesise that anti-Mi2 autoantibodies could exert a pathogenic effect by entering damaged myofibres, inhibiting the CHD4/NuRD complex, and subsequently derepressing the unique set of genes defined in this study.